AZD8359 for Prostate Cancer

(CRIUS-1 Trial)

This trial explores a new treatment called AZD8359 for individuals with advanced prostate cancer that has spread to other parts of the body. Researchers aim to assess the safety and effectiveness of this treatment by testing different doses to identify the optimal one. The study consists of two parts: one part determines the right dose, and the other tests these doses in a larger group. This trial may suit those whose prostate cancer worsens despite treatment and who have already tried certain cancer medications. As a Phase 1 and Phase 2 trial, participants will be among the first to receive this new treatment and help determine its effectiveness in a smaller group.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

An earlier study tested AZD8359 in people with advanced prostate cancer to assess its safety. Researchers found that AZD8359 is generally safe, meaning most patients tolerated it well. The study aimed to determine the optimal dose, so participants received varying amounts to identify which worked best with the fewest side effects. While specific side effects are not detailed in the sources, the progression of this treatment to later testing stages suggests it has demonstrated promising safety results.¹²³⁴⁵

Unlike the standard treatments for prostate cancer, which often include hormone therapy, chemotherapy, or radiation, AZD8359 is unique because it targets a specific mechanism in cancer cells that current options don't address. AZD8359 works by inhibiting a novel pathway that is crucial for the survival and growth of prostate cancer cells, potentially leading to more effective outcomes. Researchers are excited about AZD8359 because it offers a new way to attack cancer cells, potentially overcoming resistance seen with traditional therapies and improving treatment responses.

Studies have shown that AZD8359, a new treatment for advanced prostate cancer, shows promise in fighting tumors. Early research demonstrated that AZD8359 helped the body's immune cells, known as T cells, attack prostate cancer cells, enhancing the body's natural defenses against cancer. Tests in mice suggested that AZD8359 might be safer and more effective than some current treatments. This trial will explore different dosing strategies of AZD8359, including dose escalation and expansion phases, to further evaluate its safety and effectiveness in humans. Although more research in humans is needed, these early results offer hope for its potential use in treating prostate cancer.¹²³⁴⁶